Preoperative intravenous iron therapy and survival after colorectal cancer surgery: long‐term results from the IVICA randomised controlled trial

• DOI: 10.1111/codi.15342
• Publication Date: 2020-09-01T17:53:50Z
• Authors: E. A. Dickson; B. D. Keeler; O. Ng; A. Kumar; M. J. Brookes; A. G. Acheson
• Keywords: Interquartile range; Subgroup analysis

Abstract Aim Preoperative iron is frequently used for the correction of anaemia in colorectal cancer surgery. However, enteral intake may promote tumour growth and progression which could influence recurrence patient survival. We explore long‐term outcomes patients receiving either oral or intravenous replacement therapy as part a previous randomized controlled trial. Methods The IVICA trial anaemic to receive (OI, control) (IVI, treatment) prior their elective operation. Follow‐up analysis all recruited this multicentre who underwent surgical resection with curative intent was performed. Kaplan–Meier survival estimates Cox proportional hazard models were compare groups. A pooled group multivariable comparing achieved resolution preoperatively those did not also undertaken. Results In all, 110 116 previously enrolled eligible (OI n = 56, IVI 54). Median overall follow‐up duration 61 months (interquartile range 46–67). No significant difference 5‐year (hazard ratio (HR) 1.22, 95% CI 0.65–2.28, P 0.522) disease‐free (HR 1.08, 0.61–1.92, 0.79) observed between OI IVI. treatment groups found that preoperative led improved on 3.38, 1.07–11.56, 0.044). Conclusion recommend anaemia. Route significantly lead an advantage following